MSC-CM increases the inhibitory effect of sorafenib on hepatocellular carcinoma cells in vitro

IntroductionHepatocellular carcinoma (HCC) is the most common primary malignancy of the liver organ. Sorafenib introduces as an effective treatment in the patient with HCC, but recent toxicity concerns suggest that new strategies for its use are needed. One effective approach for reducing toxicity is to use lower doses of sorafenib in combination with other complementary mechanisms. MSC has shown a tumor growth inhibitory effect in HCC. We, therefore, hypothesized that Co-administration of MSC-CM with sorafenib could reduce the effective dose of sorafenib in the inhibition of HCC.ObjectivesIn this study, we evaluated the effect of the sorafenib in combination with the MSC-CM on progression of thr HepG2 in and in vitro condition.MethodsThe HepG2 were treated with sorafenib alone and with the MSC-CM in combination. The effect of these treatments on the HepG2cell growth and proliferation was evaluated by WST- assays.ResultsIn compared to the actions of sorafenib alone, combination therapy with MSC-CM significantly reduced the IC50 of sorafenib (IC50 changes from3.4 to 2.7.ConclusionThis study has shown that combination of relatively low concentrations of sorafenib and MSC-CM could synergistically inhibit HCC cell growth in vitro

کلیدواژه ها:

Hepatocellular carcinoma ، HepG2 ، Sorafenib ، Mesenchyme stem cell ، Tissue engineering ، Regenerative medicine